z-logo
open-access-imgOpen Access
Serous fluid: Metastatic sarcomas, melanoma, and other non-epithelial neoplasms
Author(s) -
Liron Pantanowitz,
Mamatha Chivukula
Publication year - 2022
Publication title -
cyto journal/cytojournal
Language(s) - English
Resource type - Journals
eISSN - 0974-5963
pISSN - 1742-6413
DOI - 10.25259/cmas_02_10_2021
Subject(s) - serous fluid , pathology , cytopathology , medicine , germ cell tumors , metastatic carcinoma , immunostaining , effusion , sarcoma , hematopathology , cytology , immunohistochemistry , carcinoma , biology , chemotherapy , surgery , biochemistry , cytogenetics , chromosome , gene
While most tumors metastatic to the serous membranes are of epithelial origin, cytologists should be aware that non-epithelial neoplasms can also cause malignant effusions including sarcomas, melanomas, germ cell tumors, and, more rarely, brain tumors. The differential diagnosis of a malignant effusion is accordingly broad, especially for the small round blue cell tumors that includes not only mesenchymal tumors, but also non-mesenchymal tumors, such as neuroblastoma and Wilms tumor. Diagnosing non-epithelial malignancies in effusion specimens based entirely upon their cytomorphologic features is difficult because these neoplasms often exhibit considerable morphological overlap and their cytomorphology can differ from the original tumor. As malignant cells have a tendency to round up in body fluids these non-epithelial neoplasms can therefore mimic reactive mesothelial cells and metastatic adenocarcinoma. The use of ancillary studies including immunostaining, FISH, and molecular studies is thus often critical to reach a definitive diagnosis. This review article will be incorporated finally as one of the chapters in CMAS (CytoJournal Monograph/Atlas Series) #2. It is modified slightly from the chapter by the initial authors in the first edition of Diagnostic Cytopathology of Serous Fluids.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here